Clinical trials: Age Related Maculopathy
Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration
- Trial name
- OASIS (NCT07660640)
- Testing
- observational study, VOY-101
- Where
- 4 sites in United States, Israel
- Volunteers
- 88 people
- Sponsor
- Perceive Biotherapeutics, Inc.
Age-related Macular Degeneration
Genetic Load and Phenotype in Aggressive AMD
Patients with AMD will provide cheek cell samples to determine if their is a correlation between genotype (DNA markers) and phenotype (the type of AMD the patient has).
- Trial name
- RPED Genetics (NCT01650948)
- Testing
- RetnaGene AMD LDT
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Sequenom, Inc.
Neovascular Age-related Macular Degeneration
Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
This is a randomized, double-masked, multicenter study to evaluate the efficacy and safety of FYB203 compared to Eylea® in patients with neovascular age related macular degeneration.
- Trial name
- MAGELLAN-AMD (NCT04522167)
- Testing
- FYB203 (Proposed aflibercept biosimilar), Eylea® (Aflibercept)
- Where
- 66 sites in Bulgaria, Czechia and 7 more
- Volunteers
- 434 people
- Sponsor
- Bioeq GmbH
Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
- Trial name
- Super Tuscan (NCT07205887)
- Testing
- Remigromig, Aflibercept 2.0 mg
- Where
- 55 sites in United States
- Volunteers
- 160 people
- Sponsor
- EyeBiotech Ltd.
Pigment Epithelial Detachment
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
LT1009-Oph-002 is a Phase 1b study designed to evaluate the safety and potential efficacy of iSONEP following one, two or three injections of iSONEP, as needed, for the treatment of Pigment Epithelial Detachment (PED) secondary…
- Trial name
- PED (NCT01334255)
- Testing
- iSONEP (sonepcizumab/LT1009)
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Lpath, Inc.
Macular Degeneration
Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)…
- Trial name
- NCT00845273
- Testing
- Pegaptanib sodium
- Volunteers
- 3,538 people
- Sponsor
- Pfizer
Wet Age-related Macular Degeneration
Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.
- Trial name
- DAVIO2 (NCT05381948)
- Testing
- EYP-1901, Aflibercept 2mg/0.05mL Inj,Oph
- Where
- 67 sites in United States
- Volunteers
- 161 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Neovascular Age-Related Macular Degeneration (nAMD)
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
This interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being developed as a potential one-time gene therapy treatment for neovascular (wet)…
- Trial name
- AAVIATE (NCT04514653)
- Testing
- Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2
- Where
- 18 sites in United States
- Volunteers
- 146 people
- Sponsor
- AbbVie
Dry Age-related Macular Degeneration
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
- Trial name
- NCT04627428
- Testing
- RPESC-RPE-4W
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Luxa Biotechnology, LLC
Neovascular Age Related Macular Degeneration
A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)
Study Design This is a Single-center, Phase I/II placebo-controlled study to assess the safety and efficacy of PRL3-zumab in patients with Neovascular Age-related Macular Degeneration (nAMD).
- Trial name
- NCT07547228
- Testing
- PRL3-ZUMAB, Normal Saline (0.9% Sodium Chloride)
- Where
- Singapore
- Volunteers
- 15 people
- Sponsor
- Intra-IMMUSG Pte Ltd
Macular Degeneration
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
This study will examine the efficacy and safety of pegaptanib sodium in Japanese patients with wet-type AMD, in order to establish that there is no large difference in the efficacy and the safety of the drug between Western and…
- Trial name
- NCT00150202
- Testing
- pegaptanib sodium
- Where
- 14 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Pfizer
Wet Age-related Macular Degeneration
Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
In this observational study researchers want to learn more about changes in visual acuity (clarity of vision) with proactive flexible treatments over time in patients suffering from wet age-related macular degeneration (wAMD)…
- Trial name
- XTEND (NCT03939767)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- 17 sites in Argentina, Australia and 15 more
- Volunteers
- 1,563 people
- Sponsor
- Bayer
Epiretinal Membrane, Dry Age Related Macular Degeneration
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
- Conditions
- Epiretinal Membrane, Dry Age Related Macular Degeneration, Macular Abnormalities, Retina Disease
- Trial name
- NCT07680244
- Testing
- PathFinder 1.0 on CIRRUS HD-OCT
- Where
- 6 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Carl Zeiss Meditec-Dublin CoCe
Age Related Macular Degeneration
Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD
The purpose of this research study is to determine how safe and effective subconjunctival injections of CGC-11047 are in subjects with wet age related macular degeneration at two different dosing intervals.
- Trial name
- NCT00446654
- Testing
- CGC-11047
- Where
- 8 sites in United States, Mexico and 1 more
- Volunteers
- 43 people
- Sponsor
- Progen Pharmaceuticals
Age Related Macular Degeneration
Study of WA-NG (NG-IMT) Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration
The purpose of this study is to evaluate the safety of the updated Model WA-NG telescope prosthesis (hereafter WA-NG telescope), an injectable telescope device, in patients with bilateral moderate to profound central vision…
- Trial name
- NCT04468373
- Testing
- WA-NG (NG-IMT) Telescope Prothesis
- Where
- 2 sites in Ireland, Spain
- Volunteers
- 9 people
- Sponsor
- VisionCare, Inc.
Macular Degeneration
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
This is a Phase II multicenter, dose-ranging, randomized, active treatment (monthly ITV injection)-controlled study to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered through the Implant using three…
- Trial name
- LADDER (NCT02510794)
- Testing
- Ranibizumab
- Where
- 50 sites in United States
- Volunteers
- 225 people
- Sponsor
- Genentech, Inc.
Age-related Macular Degeneration
A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the efficacy and safety of ranibizumab injection administered intravitreally to patients with choroidal neovascularization (CNV) secondary to…
- Trial name
- HARBOR (NCT00891735)
- Testing
- Ranibizumab
- Where
- 99 sites in United States
- Volunteers
- 1,097 people
- Sponsor
- Genentech, Inc.
Macular Degeneration
Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
This study aims to evaluate the optimal use, efficacy, and safety of a Treat-and-Extend regimen with aflibercept in subjects with nAMD.
- Trial name
- ARIES (NCT02581891)
- Testing
- Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- 39 sites in Australia, Canada and 6 more
- Volunteers
- 287 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
- Conditions
- Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT06190093
- Testing
- bevacizumab, ranibizumab
- Where
- 61 sites in United States
- Volunteers
- 400 people
- Sponsor
- Outlook Therapeutics, Inc.
Choroidal Neovascularization, Age-Related Macular Degeneration
EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
This study will evaluate efficacy and safety for monthly ranibizumab 0.5 mg intravitreal injections in Asian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
- Trial name
- NCT00470678
- Testing
- ranibizumab
- Where
- 6 sites in South Korea, Taiwan
- Volunteers
- 95 people
- Sponsor
- Novartis